Celldex Therapeutics - CLDX Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CLDX shares.
View CLDX analyst ratings or view top-rated stocks.

4 analysts have issued 1-year price objectives for Celldex Therapeutics' shares. Their CLDX share price forecasts range from $64.00 to $73.00. On average, they predict the company's stock price to reach $67.67 in the next year. This suggests a possible upside of 92.8% from the stock's current price.
View analysts price targets for CLDX or view top-rated stocks among Wall Street analysts.

Celldex Therapeutics' stock was trading at $38.64 at the beginning of 2022. Since then, CLDX shares have decreased by 9.2% and is now trading at $35.09.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our CLDX earnings forecast.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) issued its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported ($0.45) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by $0.09. The biopharmaceutical company earned $0.15 million during the quarter, compared to the consensus estimate of $1.70 million. Celldex Therapeutics had a negative trailing twelve-month return on equity of 21.79% and a negative net margin of 12,108.63%.

Celldex Therapeutics shares reverse split before market open on Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 8th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include OPKO Health (OPK), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP), Precigen (PGEN), Micron Technology (MU), Dynavax Technologies (DVAX), Exelixis (EXEL), bluebird bio (BLUE) and SCYNEXIS (SCYX).

Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."

Celldex Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Candriam S.C.A. (0.62%), TSP Capital Management Group LLC (0.57%), Deutsche Bank AG (0.36%), Mirador Capital Partners LP (0.23%), Simplex Trading LLC (0.00%) and SG Americas Securities LLC (0.12%). Insiders that own company stock include Anthony S Marucci, Diane C Young, Elizabeth Crowley, Freddy A Jimenez, James J Marino, Margo Heath-Chiozzi, Richard M Wright, Samuel Bates Martin, Sarah Cavanaugh and Tibor Keler.
View institutional ownership trends.

Shares of CLDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CLDX stock can currently be purchased for approximately $35.09.

Celldex Therapeutics (NASDAQ:CLDX) has a market capitalization of $1.64 billion and generates $4.65 million in revenue each year. The biopharmaceutical company earns $-70,510,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis.

The company employs 132 workers across the globe.

Celldex Therapeutics was founded in 1983.

Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The official website for the company is www.celldex.com. The biopharmaceutical company can be reached via phone at (908) 200-7500, via email at ir@celldextherapeutics.com, or via fax at 908-454-1911.